Dpy-30 Binding Peptides Avoiding RIIa Cross-Reactivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current research lacks specific and high-affinity binding peptides for the Dpy-30 domain, which are essential for understanding its functions and potential therapeutic applications, as existing peptides often exhibit cross-reactivity with the RIIa domain, leading to unintended interactions and reduced specificity.
Innovation Solution
Development of peptide-based compounds, including peptides and peptidomimetics, specifically designed to bind to the Dpy-30 domain with high affinity and selectivity, derived from radial spoke protein 3 (RSP3) and Ash2L, which are formulated as pharmaceutical compositions to inhibit Dpy-30 binding activity and modulate its functions in various cellular processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing peptides are used to bind to Dpy-30 domain, then binding activity is achieved, but cross-reactivity with RIIa domain occurs reducing specificity
Solution Approach 1:
The patent applies local quality by identifying and exploiting specific local structural features of the Dpy-30 domain binding interface. The AHD peptide sequence (e.g., residues 291-308 of RSP3) contains localized hydrophobic and charged residues that specifically interact with the Dpy-30 domain binding cavity, creating high specificity for Dpy-30 while avoiding RIIa domain cross-reactivity.
Solution Approach 2:
The patent employs parameter changes by modifying peptide sequences to optimize binding parameters. The AHD peptides are designed with specific amino acid compositions and lengths (18-25 residues) that tune the binding affinity and specificity parameters, achieving high-affinity binding to Dpy-30 while minimizing off-target effects on RIIa domain.
2Reliability
If high-affinity binding peptides are developed for Dpy-30, then research utility is improved, but peptide length and complexity increase
Solution Approach 1:
The patent applies segmentation by dividing the binding interaction into discrete, modular peptide segments. The AHD peptides are short (18-25 amino acids) and can be further subdivided into functionally important regions (e.g., hydrophobic core residues versus charged surface residues), allowing for systematic optimization and simplified synthesis while maintaining high binding affinity.
Solution Approach 2:
The patent extracts the essential binding moiety from the full-length RSP3 protein or Ash2L protein. By identifying and isolating the critical 18-25 residue AHD segment that contains all necessary binding information, the patent creates simplified peptides that retain high affinity for Dpy-30 without the complexity of the parent proteins.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides and peptidomimetics achieve high specificity and affinity for the Dpy-30 domain, allowing for targeted modulation of Dpy-30 protein activity, enabling the study and treatment of diseases such as cancer and cell proliferation disorders, while avoiding interactions with the RIIa domain.
Implementation Method 1
The Dpy-30 domain resembles, in sequence as well as structure, the dimerization and docking (D/D) domain, RIIa, in cAMP-dependent protein kinase (PKA)... RIIa binds to a 14-18-a.a. amphipathic helix (AH) in AKAPs... the binding peptides to the Dpy-30 domain will become powerful tools
Data Source
AI summary
Disclosed are compositions and methods for modulating Dpy-30 binding activity. The compositions may include peptides or peptidomimetics thereof that are related to radial spoke protein 3 (RSP3) or absent, small, homeotic discs 2-like protein (Ash2L) and that bind to Dumpy-30 protein (Dpy-30).